EBV RELATED TUMORS

$225,914P01FY2001CANIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Paper 39008818 Paper 37198064 Paper 36840972 Paper 36549386 Paper 36519323 Paper 35149193 Paper 34753870 Paper 34495306 Paper 34107771 Paper 33832817 Paper 32961372 Paper 32813874 Paper 32791046 Paper 32649866 Paper 32343796 Paper 31730920 Paper 31550496 Paper 31492679 Paper 31010834 Paper 30898762 Paper 30878319 Paper 30599208 Paper 30190282 Paper 30087106 Paper 29954931 Paper 29909152 Paper 29616857 Paper 29452245 Paper 29353109 Paper 29325830 Paper 29296954 Paper 29242852 Paper 29198753 Paper 28807769 Paper 28754309 Paper 28711728 Paper 28062216 Paper 28049637 Paper 27888014 Paper 27846611 Paper 27775549 Paper 27693555 Paper 27687020 Paper 27496639 Paper 27400069 Paper 27213183 Paper 27211264 Paper 27198129 Paper 27071449 Paper 27000732 Paper 26975880 Paper 26819054 Paper 26718103 Paper 26713094 Paper 26648070 Paper 26635307 Paper 26622998 Paper 26590771 Paper 26343947 Paper 26305035 Paper 26292764 Paper 26261255 Paper 26183076 Paper 26130705 Paper 26047326 Paper 26039204 Paper 26034113 Paper 25995224 Paper 25915157 Paper 25814532 Paper 25706884 Paper 25316679 Paper 25267759 Paper 25217413 Paper 24862638 Paper 24807964 Paper 24732780 Paper 24712979 Paper 24660868 Paper 24517426 Paper 24472813 Paper 24296490 Paper 24225944 Paper 24092259 Paper 24043786 Paper 24013666 Paper 23871780 Paper 23828278 Paper 23769818 Paper 23651669 Paper 23353119 Paper 23233586 Paper 23206845 Paper 22955919 Paper 22954723 Paper 22835045 Paper 22540908 Paper 22461639 Paper 22445004 Paper 22343727

Abstract

DESCRIPTION: (provided by Applicant) Epstein-Barr virus antigens in tumor tissue serve as tumor specific markers and can provide a target for prevention of tumors in high-risk populations as well as for specific tumor killing. The overall objective of this proposal is to study methods of immunologically targeting EBV-associated tumors, specifically post-transplant lymphoma and nasopharyngeal carcinoma. Strategies to be pursued include adoptive cellular therapy targeting viral antigens in patients with post-transplant lymphoma, nasopharyngeal carcinoma and other EBV-associated tumors; a cellular vaccine to induce or enhance response to viral antigens in patients at risk for post transplant lymphoma; and strategies for the induction of viral antigen expression in tumor cells of patients with post transplant lymphoproliferative disease. These virus-associated tumors are seen as models for tumors in general in which tumor-specific antigens have been identified and the development of new therapeutic approaches.

View original record on NIH RePORTER →